<SEC-DOCUMENT>0001571049-15-004023.txt : 20150512
<SEC-HEADER>0001571049-15-004023.hdr.sgml : 20150512
<ACCEPTANCE-DATETIME>20150512161331
ACCESSION NUMBER:		0001571049-15-004023
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150512
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150512
DATE AS OF CHANGE:		20150512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		15854610

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>t1501140_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Section 13 or 15(d) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of the Securities Exchange Act of 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Date of Report (Date of earliest event reported):
May 12, 2015</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Exact name of registrant as specified in
its charter) </B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD NOWRAP STYLE="width: 33%">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 32%">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 33%">&nbsp;</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: top; font-size: 10pt; text-align: center"><B>Delaware</B></TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; font-size: 10pt; text-align: center"><B>000-50626</B></TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; font-size: 10pt; text-align: center"><B>91-1707622</B></TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(State or other jurisdiction</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>of incorporation)</B></P></TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; font-size: 10pt; text-align: center"><B>(Commission File Number)</B></TD>
    <TD NOWRAP STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(IRS Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Identification No.)</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>200 Connell Drive, Suite 1500</B><BR>
<B>Berkeley Heights, NJ 07922 </B><BR>
<B>(Address of principal executive offices and zip code) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Registrant&rsquo;s telephone number, including
area code: (908) 517-7330</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-left: 0.5in; margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 93%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Former Name or Former Address, if Changed
Since Last Report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see </I>General Instruction
A.2. below): </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 97%; font-size: 10pt"><B>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-family: Wingdings">o</FONT></TD>
    <TD STYLE="width: 97%; font-size: 10pt"><B>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-family: Wingdings">o</FONT></TD>
    <TD STYLE="width: 97%; font-size: 10pt"><B>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-family: Wingdings">o</FONT></TD>
    <TD STYLE="width: 97%; font-size: 10pt"><B>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </B></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 2.02 Results of Operations and Financial Condition. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The information set forth under this &ldquo;Item
2.02. Results of Operations and Financial Condition,&rdquo; including the exhibits attached hereto, shall not be deemed &ldquo;filed&rdquo;
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference
into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such
filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Attached as Exhibit 99.1 is a copy of a press
release of Cyclacel Pharmaceuticals, Inc. (the &ldquo;<B>Company</B>&rdquo;), dated May 12, 2015, announcing certain financial
results for the first quarter ended March 31, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Company will conduct a conference call to
review its financial results on May 12, 2015, at 4:30 p.m., Eastern Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">This Form 8-K contains certain forward-looking
statements that involve risks and uncertainties that could cause actual results to be materially different from historical results
or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements
regarding, among other things, the efficacy, safety and intended utilization of Cyclacel&rsquo;s product candidates, the conduct and
results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding
partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that
appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical
trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated
with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners
for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that
include the words &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;should,&rdquo; &ldquo;believes,&rdquo;
&ldquo;estimates,&rdquo; &ldquo;projects,&rdquo; &ldquo;potential,&rdquo; &ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;intends,&rdquo; &ldquo;continues,&rdquo; &ldquo;forecast,&rdquo; &ldquo;designed,&rdquo; &ldquo;goal,&rdquo; or the negative of those
words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties
the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with
the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of
the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information,
future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(d) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 8pt">
    <TD STYLE="vertical-align: top; width: 10%; font-size: 8pt; text-align: center; border-bottom: Black 1pt solid"><B>Exhibit</B><BR>
<B>Number</B></TD>
    <TD STYLE="width: 1%; text-align: center; padding-bottom: 1pt; font-size: 8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 89%; font-size: 8pt; text-align: center; border-bottom: Black 1pt solid"><B>Description</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt">99.1</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Press release announcing financial results for the first quarter ended March 31, 2015, dated May 12, 2015.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 8%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 42%; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">By: </TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">/s/ Paul McBarron</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Name:</TD>
    <TD STYLE="font-size: 10pt">Paul McBarron</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Title:</TD>
    <TD STYLE="font-size: 10pt">Executive Vice President&mdash;Finance, </TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Chief Financial Officer and Chief Operating Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: May 12, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>t1501140_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><img src="complogo.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER
2015 FINANCIAL RESULTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I>&mdash; Approximately 20% of prespecified
events remaining in SEAMLESS before study unblinding &mdash;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I>&mdash; Received FDA clearance for the
first-in-human Phase 1 study of CYC065 CDK inhibitor &mdash;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I>&mdash; Conference Call Scheduled May
12, 2015 at 4:30 p.m. Eastern Time &mdash;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Berkeley Heights, NJ, May 12, 2015</B>
- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; &ldquo;Cyclacel&rdquo; or the &ldquo;Company&rdquo;), a biopharmaceutical
company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious
disorders, today reported its financial results and business highlights for the first quarter ended March 31, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&rsquo;s net loss applicable to
common shareholders for the first quarter ended March 31, 2015 was $5.0 million, or $0.19 per basic and diluted share, compared
to net loss applicable to common shareholders of $4.9 million, or $0.25 per basic and diluted share, for the first quarter ended
March 31, 2014. As of March 31, 2015, cash and cash equivalents totaled $29.4 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&ldquo;Approximately 20% of the prespecified
events remain to be observed before we unblind SEAMLESS, our pivotal, Phase 3 study of sapacitabine in patients aged 70 years
or older with acute myeloid leukemia (AML) who are unfit or have refused intensive chemotherapy,&rdquo; said Spiro Rombotis, President
and Chief Executive Officer of Cyclacel. &ldquo;We expect this to occur between the second half of 2015 and the first half of
2016. As we continue study follow-up, we have begun preparations for submission of a Pediatric Investigation Plan (PIP) to the
European Medicines Agency. In parallel with sapacitabine activities, we are progressing development of CYC065, our novel, second-generation
cyclin dependent kinase (CDK) 2/9 inhibitor. Following submission of our Investigational New Drug (IND) application, we have received
clearance from the U.S. Food and Drug Administration (FDA) to begin a first-in-human, Phase 1 clinical trial of CYC065, which
will commence following institutional review board approval. We have cash resources for the next two years which are sufficient
to advance these programs and deliver on our key milestones.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Business Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>Sapacitabine</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Continued
                                         follow-up of elderly patients with AML enrolled in the SEAMLESS Phase 3 study. The study
                                         is powered at 90% to detect a 27.5% reduction in the risk of death (event) between the
                                         experimental and control arms. Approximately 20% of the prespecified events remain to
                                         be observed before mature data become available for analysis.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Continued
                                         follow-up of an expanded cohort of older patients with myelodysplastic syndromes (MDS)
                                         following front-line treatment failure enrolled in a Phase 2 study.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Continued
                                         follow-up of patients with advanced solid tumors enrolled in a Phase 1 combination study
                                         of sapacitabine and seliciclib (Cyclacel&rsquo;s first generation CDK inhibitor).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Planning
                                         an expanded cohort of the Phase 1 study of the sapacitabine and seliciclib combination
                                         regimen </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">in an enriched
population of gBRCA positive, breast cancer patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>CYC065 (2<SUP>nd
</SUP>generation CDK inhibitor)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Submitted
                                         an IND application to the FDA for CYC065, the Company&rsquo;s second-generation, CDK2/9
                                         inhibitor.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Received
                                         FDA clearance to initiate a Phase 1 clinical trial with CYC065. We plan to commence this
                                         first-in-human trial following institutional review board approval.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Presented
                                         preclinical data at the American Association of Cancer Research (AACR) 2015 annual meeting
                                         demonstrating the therapeutic potential of CYC065 by showing that it inhibits key cancer
                                         and leukemia survival mechanisms and causes death by apoptosis in cancer cells. We believe
                                         that CYC065 is effective against AML, and in particular, AML with genetic abnormalities,
                                         such as MLL rearrangements (MLL-r), which confer a poor prognosis. CYC065 was also shown
                                         to be effective against uterine cancer cells including those resistant to chemotherapy
                                         and was especially potent in uterine cancer cells in which cyclin E, the partner protein
                                         of CDK2, was amplified or overexpressed. In each case CYC065 showed synergy with available
                                         anticancer agents. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Other </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Completed
                                         a public offering of shares of common stock for proceeds, net of certain fees and expenses,
                                         of approximately $9.2 million. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>First Quarter
2015 Financial Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Grant Revenue</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue for the three months ended March 31,
2015 was $0.5 million compared to $0.4 million for the same period of the previous year. The revenue is related to previously
awarded grants from the UK government being recognized over the period to progress CYC065, a CDK inhibitor, to IND and complete
IND-directed preclinical development of CYC140, a Polo-Like Kinase 1 (PLK 1) inhibitor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Research and Development Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expenses were $4.3
million for each of the three months ended March 31, 2015 and March 31, 2014. Research and development expenses related to SEAMLESS
were $0.4 million lower during the three months ended March 31, 2015 compared to the same period in the previous year due to certain
SEAMLESS site startup costs not being required in this quarter, which costs were partially offset by increases in spending primarily
related to grant funded research and development programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>General and Administrative Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">General and administrative expenses for each
of the three months ended March 31, 2015 and March 31, 2014 were $1.5 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Based on current plans the Company estimates that it has capital
resources to reach beyond the availability of mature data for final analysis of SEAMLESS and continue existing programs through
late 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Conference call and Webcast Information:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cyclacel will conduct a conference call on
May 12, 2015 at 4:30&nbsp;p.m. Eastern Time to review the first quarter 2015 results. Conference call and webcast details are
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Conference call information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">US/Canada call: (877) 493-9121/ international
call: (973) 582-2750</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">US/Canada archive: (800) 585-8367 / international
archive: (404) 537-3406</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Code for live and archived conference call
is 38615845</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the live and archived webcast, please
visit the Corporate Presentations and Events page on the Cyclacel website at <U>www.cyclacel.com</U>. The webcast will be archived
for 90 days and the audio replay for 7 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About Cyclacel Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Cyclacel is a biopharmaceutical
company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious
diseases. Sapacitabine, Cyclacel's most advanced product candidate, is the subject of SEAMLESS, a Phase 3 trial, which has completed
enrollment and is being conducted under an SPA with the FDA as front-line treatment for acute myeloid leukemia (AML) in the elderly,
and other indications including myelodysplastic syndromes (MDS). Cyclacel's pipeline includes an oral regimen of seliciclib in
combination with sapacitabine in a Phase 1 study of patients with Homologous Recombination (HR) repair-deficient breast, ovarian
and pancreatic cancers, including gBRCA positive tumors, and CYC065, a novel CDK2/9 inhibitor, with potential utility in both
hematological malignancies and solid tumors. Cyclacel's strategy is to build a diversified biopharmaceutical business focused
in hematology and oncology based on a development pipeline of novel drug candidates. Please visit <U>www.cyclacel.com</U> for
more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Forward-looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This news release contains certain forward-looking
statements that involve risks and uncertainties that could cause actual results to be materially different from historical results
or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements
regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates, the conduct and
results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding
partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that
appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical
trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated
with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners
for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that
include the words &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;should,&rdquo; &ldquo;believes,&rdquo;
&ldquo;estimates,&rdquo; &ldquo;projects,&rdquo; &ldquo;potential,&rdquo; &ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;intends,&rdquo; &ldquo;continues,&rdquo; &ldquo;forecast,&rdquo; &ldquo;designed,&rdquo; &ldquo;goal,&rdquo; or the negative of those
words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties
the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with
the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of
the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information,
future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Contacts for Cyclacel Pharmaceuticals,
Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Company: Paul McBarron, (908) 517-7330, <U>pmcbarron@cyclacel.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Investor Relations: Russo Partners LLC, Robert
Flamm, (212) 845-4226, <U>robert.flamm@russopartnersllc.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-weight: normal">&copy; Copyright
2015 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel&reg; are trademarks of Cyclacel Pharmaceuticals,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CYCLACEL PHARMACEUTICALS, INC.<BR>
CONSOLIDATED STATEMENTS OF OPERATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(In $000s, except share and per share amounts)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Three Months Ended</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>March 31,</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2014</B></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2015</B></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Unaudited)</B></FONT></TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Revenues:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Grant revenue</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">396</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">512</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total revenues</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">396</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">512</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,344</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,342</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,462</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,468</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,806</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,810</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Operating loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,410</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,298</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Change in valuation of financial instruments associated with stock purchase agreement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(47</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Foreign exchange gains (losses)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(378</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other income, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Total other expense, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(36</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(377</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Loss from continuing operations before taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,446</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,675</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Income tax benefit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">569</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">763</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net loss from continuing operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,877</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,912</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Discontinued operations:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Income from discontinued operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Income tax on discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net income from discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,869</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,912</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Dividend on convertible exchangeable preferred shares</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(50</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(50</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss applicable to common shareholders</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,919</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,962</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Basic and diluted earnings per common share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss per share, continuing operations&thinsp;&ndash;&thinsp;basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.25</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.19</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net income per share, discontinued operations&thinsp;&ndash;&thinsp;basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.00</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.00</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss per share&thinsp;&ndash;&thinsp;basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.25</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.19</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Weighted average common shares outstanding</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">19,530,322</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">26,067,078</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CYCLACEL PHARMACEUTICALS, INC.<BR>
CONSOLIDATED BALANCE SHEETS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(In $000s, except share, per share, and
liquidation preference amounts)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>December 31,</B></FONT></TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>March 31,</B></FONT></TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2014</B></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2015</B></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Unaudited)</B></FONT></TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Current assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">24,189</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">29,363</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,640</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,514</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Current assets of discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">171</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">147</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.35in">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,024</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Property, plant and equipment (net)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">387</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">333</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.35in">Total assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">29,387</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">35,357</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,792</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,007</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Accrued and other current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,626</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,054</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Current liabilities of discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">75</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">75</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.35in">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,493</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,136</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Other liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">206</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">192</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.35in">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,699</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,328</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Commitments and contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Stockholders&rsquo; equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Preferred stock, $0.001 par value; 5,000,000 shares authorized at December&nbsp;31, 2014 and March 31, 2015; 335,273 shares issued and outstanding at December&nbsp;31, 2014 and March 31, 2015. Aggregate preference in liquidation of&thinsp; $3,989,749 at December&nbsp;31, 2014 and March 31, 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Common stock, $0.001 par value; 100,000,000 shares authorized at December&nbsp;31, 2014 and March 31, 2015; 23,199,469 and 34,388,485 shares issued and outstanding at December&nbsp;31, 2014 and March 31, 2015, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">330,962</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">341,415</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Accumulated other comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(480</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(691</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(308,817</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(313,729</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.35in">Total stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">21,688</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">27,029</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.35in">Total liabilities and stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">29,387</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">35,357</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">SOURCE: Cyclacel Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>complogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 complogo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`:`*1`P$1``(1`0,1`?_$`*\``0`"`@,!`0$`````
M```````'"`8)!`4*`P$"`0$``00#`0``````````````!@0%!P@"`PD!$```
M!@(!`@8"`0($`P,-```"`P0%!@<``0@1"1(3U5:6&"$4%2(6,2,D"D%1%V$R
MMT)28B5%=2;6.'B8.5D1``("`0,#`P,"!`0$!P$````!`@,$$04&(1(',2(3
M05$(,A1A4B,5<4)B0S-C)1:!D:%RHJ,T%__:``P#`0`"$0,1`#\`]_&`0K?/
M(:H^-4&56%<,N11=B*$-.W)Q:$K>Y$YZ*$:6S1ME3^)<\.AVM?\`<+#X"P[\
M9HBR]"'J5\/X3R7GF[QV7C&-/(S'UD_2NJ&NCG;-^V$%]V]7Z14I:)P?R!Y'
MX=XPV&?(^9YD,3`3:@OU6W3TU5=-:]UDW]DM(KW3<8IR7G/NGO&<G+QD@X)Q
M/@:V!(EQHD[4-MC^K%MMZ+ZBUH\"(M"YL;&$T`?%Y9*1483^?]3OIUS>#BOX
MP<!XE@_WCR-F0S+8+6?=9^VPX/[=SE"RS3TU<X)_R'FOSC\T?*?/-S?'_$6W
MSV^BQZ5N%/[S<+5]^U0G55JNO;&NQQZ_U600Y\,^ZC?Z4Q[LAILM8@6`V>:.
MX[59HZGUH.Q)O`='GN2%G-X]`ZZT`:(KJ7_AUUO62^CRE^/'#+%B;%9@1NB]
M%^RQ)V/[]+*ZFI?XJ;ZD`RO"?Y9>0ZGG<FJW2S'FM7_<L^NE?;K3;<G!Z>B=
M<>GIT,-#VX.X+6IA\AA,(7*5B,@TTY=45KQ-P?"B2];UO0$S')T+X<,W0]Z`
M6248,?7>M:RZ/SGX7WZ*PMVRX1JDTE',P[HUM_XV52K6GU;:2^Y95^,_Y%<7
ME+<MBP;)7PBVY[?GX\[4E_IJOC:]?HHIM_8[Z$=Q;N"<4).3%;'>)8]`;A!"
MKKOD%&W`:TQ,4$)/EHWM<G;)@E+"6#6BQE+#4^MZZ^`6M[UNCW;PAX7\C;>]
MQV.K&J<U[<G;K8]J;Z^ZN+E2WKZJ4(R^FJ^E?L/Y)_D3XBW6.T\FOS+XU-=V
M'N],W)Q73VVR5>1%:+VN-DH?71KU]`/#+N:T?RVVDB*G?_2^Y!%?U5Y(EY1Q
M#^(L'B.40B0>4E2R$&M:V(240"5Y8>N]DB`'9F:9>4O`?+?&W=N4/^H<7U__
M`$U1:=>OHKZ]6Z_MWZRK;_S)OM/1#PG^4?!/,'9L]O\`TKFK77#NFFK=%U>+
M=I&-WW=;4;4M7V.*[C9)F"C9H8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`
MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`
M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@$+<A+W@W&NI)=<%A*A
ME,,71:&0WIADA<Y"\JA>0SQQF*/&6`]T=UH@EEZZ]`!\1@N@`"WJ5<*X?N_.
M^2XW&-EBGF9$^LGKV5P76=LVM=(0CU?W>D5U:1"/(W/]A\8\/S.9\CFUM^)#
MI!-=]UDNE=-:;6MEDM$OLM9/VQ;7F;KNF[N[IUERKD_R.F>JLXX0HY>4K?SE
M`4;,Q1MHV):LA5:EN>_T"0MR;>MNKXI",&CQ"$/1QW0D&^N]\HXG^/6PX_C_
M`(-B_P!QYSE*+5:7=.RV?MC?E=GN?<_^#1'1]J27;'W/R[XWPKG7Y8<GR_*G
MDO._M/C/!<U*UR[:ZJ:_=+&PE/V+LC_Q\J::[FV^^?L4H-G*:1J'5QXT=H/C
MT4T,R7_1R*[!1TISE\C'K84ADD6OLHW_`!L>:%(@>,E:^G&'&:WK9"9-_2'<
M?R/'N##&ASS\F-Z=N5+W58'R.%-7U^*-=7NLFO24,>*BO2=D^K)5B^6-SLR[
M/&'X;<<5.##VW;G\*GD7/]+NE;?[*:WIK&S*DY/UA55T17NSN,ZX]V7*.:W<
MGKADFAA!AKC$DC_-[YDK:HT8(T;4Y,S*K:VQK&`1F_"04'181[V$`=AUUR:[
M#SVF&-"'BK@F=;M2:4;I5T;?5->G?&<XSG/TZR?5KJWJ8ZY3XNR+,RRWSAY.
MVRC>W%N>/&W*W6Z#U;=<ZZI0A7IJ](1Z)ZJ*TZD5M?&"B3U:7=%]QVJ`2L:C
MP)D\YC=E4($Y27H)R3263'&.Z(OQFZUK1APB@!'K6M;WOIDBR.?\OA7)<OX-
MN/\`;NWJ\>W%W#1/I+6I*$O3Z13;1$L3Q5P&RV+X#Y+VA;LY:)95.;M*<EUC
MVWMV16K]')Q2?\259C=7+[CVWM5<\VZU0<FJ"D.P`:1V*I0S5K=46P%]'*IN
M0+#MP7M;Z!/H(B=F*SC@:_`B@==[U'-LXKXSYK?9OGB?/GL',J/U_ME*B<)=
M?;F;=9VQG7KJI:0C%_23]"6[SSCS)XYQJ>-^=-KKY3X]R=%6\R4<F%D>GOV_
M=ZN^<+>W1QULE)?6"U;,FK_MO-G(,^*\@N&US-K-2)$B*<)&5:"IT:[5HM]C
M"E([O+.H$Q-ZQ%)E3,C$6I0JRU*79I8R]B&+6_-W;=^\\6<$HR^(^5MLG/D\
M<:79+%4)8>?59&48V?U)*549M.-D'&?:U+1)^U7KB_XP5>3LK!YYX.WFNOAD
MLN+LCFRG#<-LOJE"<ZG\4)1OE6G&=4U.MR3BW)KWN_?;J_W"7!ON3<HK`XDT
M<AMYIG,/9'Z0PR46!%6EKBUOQN(*4J&1O47.:']X<F<XG]H"LE,[)D)RA$+9
MFM!,",D/G!)J4G)+1-^GV_@>O4(N,%&3<FDEJ_K_`!_\3>_G$Y#`&`,`8`P!
M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`
M,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P
M!@#`&`>>7N`&2GG#SKJC@K#G12@@E<$$2^U'%$9H1:%:N0$.S\[*"_Z"C%<>
MAZM,C;PF;WT<'86OQXLW7\,QV[Q+XAW'R]NE<9[QG-TXD9+K*,9.%<$_7MLN
MC*=FG^W2G]#SB_(>6[>=_/NT>`]EME7L&V161GSB^D)2@K+;&NB<J<>4*Z4_
M][(:^IV_*%H=.1]SPCM@\:S2JXX^TC'V5YY!R-D\H#:S-"$"98G8E@_,"0O-
M;"CRC?(/%_K7Q5YBGQ:2F"RF\?9./P;BV7Y_YVGG<TW:Z<-MJLU[ISEK%V1Z
M:Q4FFNZ*]E$.VO1V117>5</*\E\VP/Q7\8M;9XZV+'JLW>ZK10KKAVR54GJE
M-P3C+MF_ZN59W6ZJJ3([WHVW8K,J:XH2ILXD=NRCE"ILN?DRH-$AD]QOS8G`
M5(#4+ULU`ZR0:P0=`UX3BM*_-+\S>P&)D.[WK'C6XXO*/(V/9R3S=N\5/!VM
M+NJPJYO6M2AI*%7;Z]8OLT>G6-EQ&])\QVG,X5XBRZN'_C?L4I0W+>V^V_<;
M8)*UPLUC9<Y^G24?D[H]S[958Y@%;T[53@RFN'$GMX.%Z1-%T/UR-Y@S?^QH
MI*#2AEEC=H]''E;'VM8SJ3C!#_ROUQ"UTT,'BUO67G?>3\BIRE1Y)YM#:-RG
MT_MFRT?/=4GU[++81LG&:22Z]R7T>C(_QGA7$<C">1X@\<V;]M$.O]YY#E?M
MJ+VM%\E--DZ:Y5R;;]KB_I*.JT.OLVL`HF-?)>07:\A1<`&(9KK:?"ZSM*W:
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M1VL;$E"@CD9-VA-'I<V.,S3V"8T6^U7!(;`<$]D0A$R5LE1FMAJ("98I4#$5
M_J`Z3)A:8<LYAR/G&[/>^3Y,LK<7",%)J,5&$==(QC%1C&*;;T26K;;ZMGHC
MP7@'$O&VQ+C?#,.&%M"ME8XIRFY63T[ISG.4ISDTHK64GI&*BM$DC;?PX[*O
M;KX%\@K&Y-\9J0'"K6L9(]-@UZZ6221LL(8Y(X$.D@8:X87I>K01%J=EJ8OQ
MA)T,PH@.DQ(RTO\`DY&28FUC`&`,`8`P!@#`&`,`8`P!@#`/X,,`4`9IHP%E
ME@$8888+0`%@!K8AC&,6]!"`(===[W^-:P#'&":1*4C$7')(RO9@4*1T\MM<
M$RL8VI>(X"!U*`48(1S4O&G,T0I!H1!VP"T`8O#OH!DV`,`8`P!@#`&`,`8`
MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`
M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`-%/:Y/13.7\Z^;S^6!2*66#(&M@
M>CRP$`*B<?3J9>ZDE!`89^L`:-0UA-UH.M:TF#TWO7XUMY^04+=KVSB'B;#;
MBL;"KG9!/76ZQJF#>J6O56M?^YF@_P"*=E&][SS[SKN"4Y9>XW0JL:2TQZ5+
M(L2T;T3BZ%+I_D6G0A*JTTT9NWW,[-:3C4O(+N4\@R86DD1A@?Y)`S61,G&.
M$B*,Z)U&T"&-I7=2'9>]Z#I;H?\`3K7],KY#9M65YHQ=AR$I<+X)LKO=:7ME
M/%HC:]5U7=*UTQZ^OQM==>L(XI5OF#^/&;RC%;AY%\F\B6+&UOWPKS,F=*T?
MMEV1ICDS7:^GRIZI+I/%AUW7S4YZJ$B-*9#Q=X(,5>1UHIY`<22#DAR^L<"%
M5"(])-!'O3HE;1OR!2M"HT,K]]W,--`,@L8<B&R;WO611_W-/(C1Y!YA=DVS
MS9)O^V;-B]ROLJZ>QR^.R,''1_'3&,6IR3)]R+CG'<7+_P"SJ\:>3XKX#CXE
M->W1:7]YY#F]LL:F[K[XP^6J=JGJOER)RFG7&2+@1?@BP6.F0S'F4YJ+TL16
MG),_LH+N],U%5DGZA,31"N:\9UC6UJ&QG)T%,->Y@5*W#P;,'X-"T`.,MP\O
MYNQV3VOQ=7':-DC)KY^R$]PRGZ.[)R9QG-2F_<JZG"%>O:M=-7F7:O`6W<FJ
MKWKS5;+?N1SBG^V^2VO:\%>L<?#PZY5P<*UI!VW*=ENG=+MU[5BUI<"..]7M
M2JUJ4L`SA!+8V<D/U9<=E0VJM@;7N:-"4VSZ%RM^30A[8W=4J+2!2C$C\PXX
ML`1;WO0!=FW>=.2Y4'MOD"JCD?'9K2=.5&$;H].DJ<J$/EJL3ZJ?O_P^JZ]V
M_&CAV':MY\67Y/$N6UO6%^'.R5$NO6&1A66?#?5):IU^Q>FK:6CQ!!0MBW;8
MB%N@C"#C%Q:BEJ\D*LYK\>;)XY5T0B[@S/(ZZ:XDRVA#)(R29V61^L'=Q=%!
MR53L*98X%%FE&D`"6$(\5;WR#=^075V;KDY&1"BOXJ5=;*UU4IMQKC*3U[8Z
M_P`-?4S=QSBNP<5Q[:MDP\3$MRK?FR'13"E7WRBE.Z<8+3NEI]WHNFI>+C'Q
M6X]\-*E::+XQ5;'J@JAD<79X01".#<U*;3N^JMK'=T6N+VX.KTZN2\_IXSU2
MDXWP``#0M```(;*2(L#@&E*W^]U3K9>4]XQ\/>.7)KN)7G5*T35;#9Q:AS(O
MJ^J'TM::W'1VQ+FF+_'H:S/I"\D9)A*7:X)1Q1I1@P&DFE@`XLS[P\\JOBQ?
MG)FY>V=S8J+?&1RA"BV*]FJ"M"G%;7LO4NB-RL^J94TS-TB]F1JOSFT(G\))
MJ,Y"0>`[H,H)@P`;4X'R!IZRJ%C?)R)3MC7T9*:S36^V6&8K+3L1=>GQ_<G.
MD+BH,%K3>G;&<`S%@3?"-*(HP!F@B`+6@*$<>.[KQZN7A98_<-LAEDW&/B+$
M9;+&B&6?=!B!&?:L-C+]_:R*Q8I%V/;F^A:9C)M";V9`(L;JX*P"++(WO9>Q
M@5HC_>\LNUV=/9?'#M#]R:[N/RQ(6[,]P%0:M:^.F\>.,V!-):TKR:V`AELV
M9G$(=F)!%@3FGD["9Y8`BP"X-@=S:OJ[Y&=NSC:_5!;;7,.XO'9[(81_<2%B
MCKA48J^K]!8#NP6Q'E+LH<6^2EIE^D)J9$)7I.M*&$0]AUH6P-F.`:@NZOWC
MJ.[4:6H"K'K.T+GE5N_WR])834)+&LD48KJLVI&ZSNRY"0].*`M-%V$IP)`(
MSKK0A;'U$$)8]Z`VGU_.HS:$"A-EPIQ+>(=8D1C<YB;L5T\ITC,M9D3^Q.)?
MA$,/EK6MP*,UTWO707^.`:HN1O>@H^J;_E/$?CS1W(_GKRE@:,E79%6<3X,W
M2EHJ41YF@%([;LJ1OL=AD+<-_P"`TX3EBE.;O19Y91F_#@&<TGW*)_.(WR'<
MKX[?7+[B2^<>*7D=WN15NM5?ND"L2/QEI<71PC];6A"I@]QY\EY`6[>C49I:
M;1)9H#!#W_6$`%'J6[]5S\BZLB=V4?V:.X39=5SM"L<H?-XT.EU+)(4:!R7,
MZM0W&FSLA0:40Z-IY&]^7K>QE;Z:W@&P"\.YG!Z"Y2=O?B=-ZBL<FPNX,CF9
ML64`41PI#4[C!8W'I`^,U@DG..E:AP)'(`I?_5X5`-'D#Z[\/AWL#8C+XXFF
M,3E$16J%"1'*8Z]1Q6J2;!I6F3/;:I;#U"79@1EZ4$E*MB!X@[#XM:ZZWK`*
MF<8^';9QTE$DE9$L<W];(TS]^V0L4KU9/\M+'QK?9(K1"<%!PVB._M,2732R
M$^-.SA,5:`<=I1_0!=7`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P"J',GE2V<1ZD;9R&$/-J6#/K(KZD*/J&/.;<Q/
M%K77:SZ7'X+#"I&\!&T1=J$;L]P=G94$PEJ9D"M7LH[9.B3`()KKDYS+@MJ)
M8+S8XNU[!Z[DU=SJQF3D3QBLR?W?4M=&URW%/LE@%^"F5.U7(("\J8^,:AC>
M$Z=<U/IR8Y*`*92$LHT"TBGE;QN1-U7O*VZZ\1LMT5E*KIJ][5R)$F99A4<'
MBC+.9A9;<[GC+;B81&8C(T#@M<E!I*1.G6$B&/6S`ZV!36>=V'C8LK!-8'&B
M:0_D(X).0G$>EI9%D;L]P]XC;!RNO.&5!&[)$VOL:+>U\6/1292YLB\I)MHD
M&V\PI,M\.AFE@6!2=PGA8OO8GC4CY$0!1<RF:.]:I(L`]T_CUUG1](H6OU7(
M)KMMU`U]GLJ=(=M7'"7,;VG$28`Q*$8!!T!V$8Y[<.9E>+GQNC'(6NWBYVIR
MEC&?#DSDH"!7)(`B&Y3^),DE.2%1&1S.!-Q1BA\9F]>J=&<DHP:P@D)1FP@1
M$Y=T'B1)ZPY'2WC]<,`NZ<4#0EK7R5!&EX<68,\C581]X<5#S#'Y>S:1S2!*
M'YM*;5$BCVGAK2*%)81&;&,L`P/ER0YU2"C^VK]\F*L&F5R=74=%V(UU6YR]
M8Q,AKS=;O73(F8ELT2QMX7)VYD5S[0AJP-9IAI:?KHG6Q=-`0=+>X+RPXX6/
M'JQY?<8J/8E]L4YR9L:CY1QXY%S"U&9UEW&*L#[9DT"L9EGU"U%(8DADD43F
M#0/:`MW3%J2])E!)1IZ?9@$\<..Y]Q)Y@U_&GB+7/62"R2N/<+Y`VK7I<J$)
M-7,:>XVT.<R<B)8]MS`RRV'5U('`QI=GQ`,U"WK"?*6"3';\K0&7UUW+>"5K
MHK*<H'R6KYW0U%6BRZ)\J6"?(\4U4VW^;^Y;K=N2L[/N4U:3LG>MR%I_>9]B
M$#6E&]C!H0&'N'=L[<#7%D,T6\MJQ!'79)+G%A5$[D:M9)V>!O3<PS%_B3,D
M83WN6QN/+79.8I<FU.J0!0F?N:.VC"(_0$GUAW">$ETS:35Y5G)RHYO*(A`U
M=HO13+*$QK+NN6S]+3Y-V:6G!)B4GC$7,<4Y;PL;%RPEG..`6M$G,%H.P.-3
M7<1X3<@'*9--3<CJ\DRV`P(^UY-I4J<8LF3U,D.$0JMEK<)@W,#?):J2FZUH
MR2MAJQD+\8/$JUH8/$!P(+W)^"-D0BT;'B7*"K5,)I=A9I99K\\.RF)IXM$)
M,:<GB4S/3RQ$QKG&&356G&0Q.Z,I2VO:@/DH3U!O0&`9/7_/+B#:,43S2$WQ
M"W)C/MB%T6:6OV[QR0-=P6,O;FZ`UW((?)FMGET9D\S4NZ7;8G<4*7:TE26<
M5XBAA'L"*.6W<QXW<1]QY'*I"1)WQ7RDH?BS-V&/G+#W"L91>B%IE#8]RTE&
MU.9Y:9HKEW+?M)2RQ'KDXBRRMZ&/J$#NE/<%H*MXA,)CR#MJFH,B;>1MOT%#
M4D#ELILUZD[K6#PO3*&(R*MT%;Y@9:+(RMYBJ3LC4W.R:/[*,V)<>0#9^`<R
MP>YGP)J^*5Y.)=RBK`,5M:"G6C`WB-.#A/"7NKTJ@"-;9IA,$;I(K9JY;5P_
MUU;ZO+2M212`9)QX#2Q@"!B3IW'::B=YW/#9Y(H/%J$JOBSQ<Y+M?(7<OTZL
M,U2<H+&N>`1"/L+8UMBHMW_E#JQ0"9!MRE<J?5#T60F3['HO9P%K:'Y$TGR<
MA!UBT/8C%8\212%WB#NN:/WDB^.2]@VGT^1&61YY1MLCB,K:`JR1J6QS2)%Q
M)9Y0QE:`8`0@(LY0\H%G':<<.(>EAJ:5@Y4\IFKCDL7J'PUG'"DKE4%OVCN6
M)DY;6XZ?5!)U7`1:1C&D"(*W9OG:V5H`P.DKON.<&[9MQEHBM^3%93"UY&JF
M+;'XDT.:LTQZ?:]4.R><Q1K=S$)3`NFL4TQ*SU[(6K$[)T9`E(T^D_0W8'?U
MQSRX>6[<KIQ^K;D'7LOMYJ/EJ3^T6IQ4BV]+Z_5!0V`V0Y]/1D1F=NT`6B\I
M^2,BUP4LIFA!6@(V$70"W&`:1NUY!W(G@%R-K,PLHB5)[&Y!05T`'KX2Y`&%
MLS'L(Q]/Z]%F;!K6]=?Z=:_XYMA^0.[42\R['O\`%N6W2P=NR(?QK^>=G_KU
M-%OQ5V')A^/')>+R2CNT=RW?%L7VN_;5U:?QT>B_P/VI6@I3Q3[1DF"84G9(
ME;\!3NVE@^NBW!^A-DQ9!XM[ZE@'N5*RB@:'O6PFF`#^!]-9\Y'DRK\B>2MO
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M*,DC;51H=B1>:=L&O$/0@@2-@#`*L<YYK+*UX3<PK%@2U0VSF`\6^0$TACBD
M`,:IOE46J>6OD>7)@%]#!J$;LA),!H/YV(.NF`:R_P#;85I6$![.G$I_KH*)
M>[6ZQRVU;7E@-!.>Y=;$@G,D1R]5)7(756YND=/:P,H!G"$,"9M+!UZ:Z[`W
M@R2.,,QCK_$92T()!&)2RND<D;"ZIBUC6]L+VA/;'=I<DAVA%*D#DWJ3"3BQ
M:V$98]ZW^-X!X77/CSRLK7DI+/\`;"5_+3V_AA?E@D\JHU="B4#66#6W;J=%
M[Q);AXXMA1Q)"D;T\62QB9$JCQCWLA6H,.+,3+C/(`V&=[6L*Q;+]_V^?`=0
MRM$.X4R?E\%GDU8)$1A4(>"J08:V:*7KAX3:,TC5L3L.5+&T:53HS]G]K9@N
MHBQ"P#U5D$$)2"4R8DI.F3E%D)TY!8"B"""@:+*))*+T$LHHHL.@A"'6M!UK
MIK`/-7W0/_WS_P"WU_\`>O-W_P`&$6`>EG`/(/1MO\+^?_<Y[J/(WE;R#H&+
MTI7U9O\`VJ..<,M"WX##'1T@1Z!RWR:LB.-<KD;8<!#+I.[G)6UU3D"_91*C
M2O,ZD;#H"P'8*Y5/!7;VY3<04$PCEKW;VN)==-*Q%SC$A9I>TV/5[25+I#QS
MES&]1U<Y-CU'Y`F;5+2C&F%LL*=L+!T"+^C0&5_[4Z,107:8AUTE$(E]O\A[
MMY!V-?\`,S!)U,GE]A);>E\91J9.NT'][:A-%FA$84G/%O1?[)AP0Z_9%L0&
MZSF__P#1;R]_^UZ_O_"B68!Y1.RIR?[U,'[8?$>)\:>U[2EXT0T1*3IX#;4E
MYE0.MWZ7M)]F312XN#A!G<H;BPG(GE0K3!+,WO9@$X3-:Z#UK`+@=U\U:?WU
M?]NF<Y)0(7$Z0<JC5Z(HX*DM(M,AD`&J2EJ`]`G@3G[$#0]?@6M=?^.`>IS`
M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8
M`P!@#`*"]Q'CK:%^U15LAHK^V%M[<7^1U1\KJABTW=E4>A=AR>J5;LB>ZRDL
ME1('93%TEA5[*WMI3.FDBH#:XJDZDPH910]8!'U>V?W#;UO.N'&:<=D/!SBU
M7+'+7>]FRWYU2EU65?\`(G-C$UQN#U^"I9;+X[6]<PQ>,YW<Y*YN)3DZ^40B
M*:R21J%``-&?';@7/^6=6]SFLZQL6$2RK:!@-C=M_MRS)/(5#S6S]6B^W_M=
M/8N]R)M"XIEC`2:Z0BHWA<V@4DEH(2H)T$T9)I6P-EM[UES,YF;8W9PX-PSC
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M%M6EQY5T4PQ'C!`H&!0L75K-`FEJ5"Z<EP\#(C2HM!0FJRA;(`V/<PN'MS75
MV:2^&,8BJ)XN590G%RN'6)&2IH9$8W&O9'3RBP6\N7#=$+6G_1:(LY;*4DJP
M;,$6']<SQB+WL"1W#M><5ZCKGD,\\;J02([YL7CK;E01B;3&PK#LB7D)IM%'
M-,3$V*97)-YDLA;$_2#]0:XM$H1)E`RBQJ/%HH.P@4VDW!;EFRUWP@35)754
ME3_CSV9>4O$AR;)^HA;[6C7R,L"LN)3'7,%ED8/$X-TUKUUD=4/A2\1:5>S;
M)(Z*0C)4!":!3&4=O;GO<3C>DF751?82YWV?>:W#1A#RGY'<;Y5-CN0%Q%50
MNB4>CD(HE6WTI5E1.BF*JDC>J:]DZ,$1XW%*W$E(]G`;@2>)MC%\W*EN7^R&
M`-<0/M;V+Q<`YZ<(YYK%:LEM.FWY#%6MFTI_?):UD7AJS0UI!6D(0$!)$9K8
MP!V!1*-=OOF-".-G;3B4%KBJT]M\6^U7S)XYS%HGSC"9+6C1R+MJDZ%CM<QJ
M9,NCG)ML&"2.?01R"\C3D.#<80`8E.AEGAT8!621=L[G;R2D$O-DD3O*!-LQ
M[87)[B9J4\K^0-!3=V:KNL24<?IC'X^TUCQE"&LZYX]R(RLEC-L^/IA+3T!A
MFU;8E+)1`4@6^Y=T+SCYWP?;HCX:Q[BP\4DJXKSY@0*[CJELY(7K,:1O)MM"
M6TM75V5:[S^'5Q23(R(5"N).$A`0>HFHD2L]L;4I)Y^`1<X<%^4SS';3O^+<
M?+Z/M)BY*]N.WHM`N5/+VM[.Y`W[!N%=SOEIRN,'KHNZNU"U0L3I)JY)(F-3
M)UJAS,T=IR.;2!)@X!V]@<6^=4\?^1O)I1Q55-4EE7<X[=/,*!<?R+BIQ;8L
MCICC!7M1PF;MRJ2_WB56#/99>HFL4#;CWH#=L8-DIEZH/EGG`9M6_$OEWQHY
M'M_+5#QZ57F@:>3?=64*:<B%CU0U6.EK+FQ=%26I5=TP11/YA%:Z,>2$U0Z9
MWYI7/K:YDM[OHPK1HDYJ8T#!K5XT]QN9+PI#N-K;54<L?BN[0]EKS@5:/'R@
M817]M2NUKME#K".6%N2IJ+O255XTQ:=,B\PZM]JFQ3)SI(H`UFF+DQPP,#C?
M;3Y2LM(QIEF_')/9"^(]M_M#48;"XMR);:>LAMN[AC:]WRJU'BC;<B$E3;AE
MP52GES2]0UV5KD4>=5_1(H6A($I\(%]N&J_EGQ9C3@AOB!6Q/(Y?O,^%U_3:
M>WY%Q[>^5\%JR15(B3OEE<FIKQ_;$U>VJM9YE"%0$8B%#O)$L7$F$YN)WZAF
MB`+.\WJ$LZZ;-[=TEKQE2.[1Q]YR,5V6DH4O+4U#8Z[0\?>04!4NZ0AR5)CG
MI2"3SYL(TD2!.4[">(S0/++,$$"A]0\!^04.X\]MB!N,#9&B8<?.YIR#Y+W&
M%ND\1\]@K"RI#SK5-$O0NJ5<8G?WIQ;KNC0C$J42A<']G832_P#3G:+`RGA1
M5G,>@:YX><5I3PFK%>U\*(Y8;+(.3TGFE7R%OL=(PP.916!2'BJ@;Y,*RH1;
M=^.3PD-EBZ6-3$A9F]6[IA&.0U!)@@+#?;ON*_\`\CIU_P#FCQ-_^:,`[KC&
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MN=5<)V2BL\<],B)6O*%/6,XHC3-84!**?D4A2B&`@I0Z,3:8:XM3OK8O]3I,
M6I1:$$8_&1K_`"2X)N.ST?NYUTO]GEIOOQLANN5;]6H622C.'\O<XST:6D_U
MO)NT\@RE@PNR$]PP&E\>7B)6QNCKHG.J#<Z[/Y^Q3KU3EW0_1'O5$V=5HC$\
M<A[Z8<2HT2L=)4E.B,?;DX=!&H7&J7,O3DY%%$[WL`4:4X`Q!\(S"M=1ZI(;
M3C5)3SLJE1<=8PI:NLD_I%*+[8MOU[YQ:751EZ%?9ON7>W5MF%D.<9:2G?%X
M],%ZN3<UWS275*N$DWTE*'JLIC\E8I6W[=HVZ)7EK_;5HBW)`/9R!2>@/&E5
M_I*]!_77$%*"Q`\TD0RA"#O6A;WK?2W9N!F;==^VSJY59':I.,NDDI+5=T?6
M+::>DDGHUJNI=MNW/;]WQOWFV6POQ.^45.'6#<'VR[9>DDFFNZ+<6TTF]&=Y
ME(5YU[NTMC^U.;$]H$CJS/3>M:7=K7D%J4+DV.*8U&O0+$QNA%*$BQ*<,LP`
MM;",`MZW^-X!YJ:Q[<W=)[4S[8D6[5-C<;;^X63>:/<_C'$#F`NGD4DU#O4F
M7:7OK/3]K0T*LA=%U1_B$$EU\D`-[",1!RL2E:I`V\<'WWN.R5NL=Y[A$#XJ
MUFK5.4>!4,+XTRNP9JL:V8I,ZBE!MDR.:I$C<X.JE6:B"B_BP`)`64;Y@>H@
M[P"H$JX+7X[]^>L>X4C11/?'.*\$I!Q]=EQDE`7,@6&XS>1/Z8DB*_I[,/:-
MH7,KJIT?K6A>+7A_'Y`LIW/.W'77<QXZDTY*I=(*JL."S1BMJ@KRAH-#F%,W
M#$O/%')@TEZ4H#5R+PJ#"%J0"E*8<0/QDGIU)1"@H#7]'7#_`',50L**K389
MVQ.4JEE;B6AEY(2B;W15[J_%)->2F?K,KIH;"R3I"J3`")6!ETG3;/V+8-BU
M_4(#%^Y1PU[G5H\F.U%S,XW0;C5:EZ<*XE<"FXXW,9^_UY5CU8EK0*+1%W#$
M?/2'RH^)@5Z=#T6S3"U18"R-'==B%@$X,\][]=A4URJC5I<8N&%5V$Y\?)6T
M\:'RIKXE3HK%>4A6MT=:%DF62$I0E9V*+,#HN>0&!`$9ZUO(3^,.CMC`!S>#
MO8AX`41Q'H&J;_X:\4[TO.*UVS?]8[6L6DJXL24S"T7D(WZ>+CI?*(TX/CLT
MI9,YJ4S;L\T6RVXD@'_DX!A59=KJ9<,N\!'^47"&K:>K+@[>W&@^G.55.0=/
M%JT:8O/H@O7N]>V+"Z_9&=(V.BA68G1I5FD^B!A"I7&C\P9^]Z`BIH[:/<8[
M:5MW1-NT'9O'F><9+ZGKG:<JX+\N=39DC=8V`_GB$_N]$67!A*5C.UN(-@!I
M`N`G(*3IR2S?W!%%F@`N'7K/W<^0-.\OH5S2K'A;4S+8W'&Q*ZHN#T1/;*F4
MR,LB8120L>EUD3*5($\431<1;B045^@1H\LSQC,"(&M=0-7W`VM?]Q=P'XBT
MSQ%@G#[M\3B+4LPO+&RRJ6\BYLGD+P4\RI_EAASHG9RDC8$XE6_F%!T4$`=E
MEAZ_GKO`)[[IO"ON47ORI[4'-KBW6''Z66UPPCEIO]K5]8]H.,4@NK"LR.U\
MWJF)C<TR(YY>8Z@6-SIHI2$99OA))$+6_'O6`;`N%%E]W^86R[M?/7C1Q"I^
MFBH,ZK6644-;LNGDR56"4\Q\IG9EK._?Z,F/JF,]R..4!_S`'D$AU^!BP#:A
M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`
M,`8`P!@'R.))4DFIU!12A.H*,)/(.+`:2<2:#8#2C2AZ$`PHP`MZ$'>MZWK?
M3>`8U"8+"*TB[1!ZYAT5@$*8"#$S#$(3'FB*Q=D3G*#E9R=HC[$C0-+:0:J4
M&&B`22`(C!B%O746][`RK`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8
M!2GF'4LT>"*_Y"TJW?R-\<<W9=)HTQEF?K[LN!NB;26QJF5FAV#8_P"ZF4KQ
MH-BWORG$@KPZUL8MYE;QCR3:L6>;PKE4^SA^^51JML?7]KD0>N-F)?\`)F]+
M-/6J4M?1&#_,W$-\S:]N\C<(K^3G_&KI7TU)]O[W%G'MS,"3^OSU+6K7]-T(
M::=S9_+@5&^7-=UCR.X]RI''[2AG\@YUY('9,>$M"O4%A03JE[:94X@.1;&Z
M')OT7='OHJ;EI!*U/K9A!?F*)9WC7>\_@W-<>5W'LKMADUP:UE%/NQ\[#F_;
M\D$_DIG^BR$I53TC.7;\RJ]M\P<<VOR5XZRX8W+,'OGAW6)Z1FUVY6V[A7'W
M_%8U\617^NFR,+ZM90CW<&,/[9;\N.?HVL6<=N6T5:$;;8E;2A.G<BI(RHCS
MOU$TC92U+<EM&NAJ-'"9).SGEJD91XM`.($-0BWW;AAY'&=M6'G1AOGC?(ME
M+&RJFXNJ<DM75-J3Q,G3M^?%NBX3<4W":4+53;5N.+S+>)9^V3GQOS!B4QAF
M85Z4U=7%OMC=6I0CG8;?<\7.QYJ=<9-*=;=E#R59I>TN*Q?,:+L*+R52+:ER
MFG'N1&/,<D*P0BP&KU;8TN<8DCBN.V;O>_Y6/GB`'6]:.'X="W05?#DT1IVS
M=\+(P(](T;E5V6UQZZ14IPMJC%:?[.3%-_Y5KH72]9&)DSR-ZV#<<3=)/NGD
M[1<[:;I:I.<H5SHNG)Z_[^)-I:Z3EIJ=0:H9GG0TA=.<E;@5@/\``0WV88JC
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M$+,F[3VU4TU504M%&%T^V2G"&RA/-8PS2I(TR%D2/B32Y*V2MF51Z0IDPS#`
M$;<V1=H*UL.4%`T:$HX(#0EC#XPA%U#J);IM\]JW"W;K;*+;*9=KG3-65MZ+
M7LLC[9I/IK'5-IZ-KJ3O9=UKWS:J-VIIR:*;X=T89%<J;HQ;>G?5+W0;7N49
M)22:[DGJEDV4!=!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,
M`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`I'8=$V/65@O-]\4QM`7Z3'Z6W%
M0<@7?PU?7.<45Y?]RLKF62>7`+;+)`$L+IHH:)RT$(%P/QL[,L;)R_8]_P!E
MJX=Y%5O[/'7;A;A7'OR<%-_\*<-4\C#UZNK565=72_\`*8,Y'P'DO%N17^0?
M$KI_N&5+NW':;I_%B;DTM/GKFDUB;@DDE?VNJ[11OCZS/BWV7QGY5+D-?63'
ME<%NJ-;TN(K6R2U=<W7"W'>O\QS@C\WKD#FX(A#!U`YQQQ4)%)8=;$/IU!KE
M=L//?'=,]ZV*^.9Q2_VO*Q6LG!OC_)D5RC*$9?>K*JC.+]%]3KQN4>+O+61#
MCG)\:>!SC%]RPLU2P]SQI_6>+;"4)SCTZ7X=TZYI+5Z="3451W3$M[)A7(Y\
M=VDD!GZ;-<4*8;"-)$+R]%$F2EB4P*5+$I(0;Z;5J52D0A;V(X7XUJPV\EXK
MN7NW78J:LEM=T\*^S&3^[55BR*8M_P"B,(].D42BCAW.-G]FQ\FONPXI]M6X
MXU66UZ:)WU2Q+Y17_,G9-Z]9L_M;`N3#X7I.OY`0Z)D^/6C5%?TN06ZG)QA$
M$X):N=3>;-Z-2'6];*,TC,"$6NH@"U^-_*MXX%AR[Z=ERLF>G19.<^Q/Z=,>
MBB4E]UWK7Z-'V_C_`)1SX_%D<BPL.&O5XFVI6-/UTEE963",OY7\<M'ZI^A@
MCQ!N-_'3:6X;ZLDR12MJV/\`C++ON8$/CRC5&;#H1$#C6B4$<8G`XP>]%DQY
MH3JAZ'X->+6]:R[XN[\ZYQW<8X=@*C;K/UXNWTNN$DOKD6ZRMLBOK+)NE!::
M]/4L.9L/C/QLX<S\@[F\G=Z?T9N[9"MLC)_3$HTA35-OTCAX\)O7M6JZ'80"
MV[JO.;,+Y!H(IJWCPU*35CE+K49%:"Q[=*VC-`B10:`GGI5\)B9BDX!XW=Z"
M6N4@+T`A$$`A&YT[SQOBO$=JNQ-WS([AS:R*C&G$L4L;#?<NZ61D).-]R2<5
M30W7%MN=K:42HX]S#G'/=]Q\_8=OEM/CBF3E/(SZI0S-P7:U&.+B-QGC8[DU
M-Y&2E;-)*NA)N9;W,9F9!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,
M`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!
M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8!&]E4]5MQ-`&.T8#%IR
MVD#\U&7(6E*N4-I_4(M*FEP$#3@T+`B#K>CDII1NMZ_`LONP\GY#Q?)>7Q[,
MR,.]K23KFXJ2^TX_IG'_`$S37\",\GX9Q3FF&L#E>WXF?BQ>L5=7&3@_YJYZ
M=]<OM*$HR7W((!P\96,@:.N[UY,5JV@`$*!D8[=<),PMFP;WLL*%NLEOFXDR
M8/7IY!9H">FNGAUDP?D[*RY_+O>S[!GWM^ZRS"C59/[]TL65&K_U-.7\2`1\
M,8.!6Z>-[_RC:\9+V55;C.^J&GIV0S897;'_`$J2C_`^`N)LD<`GD2+EQRM=
MD1Q&B/U6V;Q"("UK8_&,?\A$X&T.P#!ZUX?$6>6+6O\`#?YSE_\`T?!I:G@\
M:XY7:GKK*BZ[_P"-V1.'_G%HX2\0[GDJ4-RYCRZZB4=.V&5CX_UU_7CXE=B?
MTU4T_P")F%>\0>/=;2$$S9Z_3/T^`,1FK#L)T>K(G83AF#-&<FE,X<'YU;QB
M,,%O_2F$!UUZ:UK7XRV;WY,YKON$]JRLV5.S-:?ML:$,7'TTTT=5$:X2Z?S*
M1>>.>&_'/&-Q6]X6W0R.0)Z_O,RRW-RM6V]5?E3ML@]6_P!#BBRV0,R>,`8`
MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`
M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8
M`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#
M`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`
M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P#6=?MH/;=R+E4/>KMD540I@ID,L8?
MX1P:FPM5,_&?^HG4!6MJPU[_`'-AZ?I]?$9H/0/3\X!;OC/,)O/:/K^66(D&
MEEKNT"-<1&(_X\Q<64K4$(74Q#X"])#'-"46?L&@A#U'UUK6MZU@$[8!37FQ
M/);`Z_@Y\2E2^'&2&TXK&7MZ;!I"%A$?<@+_`.1\I8L(4%H=@`5H?FZUK8/!
M^=].NL`^/&R7S1TLVXXD7,WFTZ?B^V(,+L5\$B7*CGQ01U?8ZGD;<C1(I*2W
M#WOQG`"/18PZUXM>+I@%T,`C^UW-P9:PL-X:E9J!S:X7)G!O6D;#HY(M2,ZP
M],I*V((@Z,).!H0>NMZZZP"HO!Z;K+`CP7]_N2=SV8F1L@4GB$A1A+CT<4GN
MAP4RYH7!8T):Q0>0ET`7@5'Z#H0NNM;P"_6`=/(5#HC8'Q6QI`KWI*T.2AH0
MCWT`L<R49QB!*+?77])ZH(0[_.O\<`H=PTLA=8#@Z'3BY)NZ6PE3.Q<UIV4(
MFYG:H^H"Z!"0NCK;_%IE@4J$C02M^`\?39F_,#K^G>P-A.`?F^NM;Z:Z[Z;Z
M:WOIUW_PUUZ;Z==X!K@XWVA(9E<4G:[8MJ:1JT&N4RE*GI!>A;FJ%KXN2`TM
MH$S`.;-J5RI&5K]C9A:G1IF@Z%T&#8MX!L@P!@#`&`1];+PY1ZKK%?F92)$[
MLL)D[HV+`@+,$E7H698I2*`EF@,*&(D\L(M:$'8=]/SK>L`UT47:-G.$BXU'
M,=JR>TW*R&UU7WA#G8]K?&Z$MA>C-)7T)J!O3'1`030]"DYQO4\0>FM;T+I@
M&UC`&`:PB[)?'?ES9,"E-X6%#&)FD\/3P6+QQ(!8U/*Q84@-6,;D,#"Y[1-Z
MK>]:$,PP@/0T7^9K>OP!L]P!@%-8W/)BJYMV'7RF1.)T*;*I8'IOC0QE?QJ1
MU4F-@3UQ(-%:-T>;HT77J/>OZM_C`+E8`P#6',++>S^7\WKR27?8%>0]`@@Y
MD3:(HD`N3.#^YZ:-'-2L(6)W&D0K]'BV88/90-;%O_,#@&SS`&`:^N9UIVBP
MO,>B5//BUH>8O#Y-<DV$WZ+&:KBD9/1HTK0HT,@_PDNB@P_>P_T['HK_`+,`
MNY")4@G,.B\R:QA&WR=A:GQ+L._%H);DC)5>5O?_`)Q(C-@%_P"D'>`93@%6
M^84SL6"4PO?JW_DT[@%]8TL@>F5`6YO$<B*A0/3Z]-B,TLTH2M,4$(0F"#L)
M6A['OIT\6@,GXX/L;D==ENT6MJ17"UJG-08!_E8T6Y`U&"(2^9'W$I*@;32#
M40^H_"<7YG0W\"$#P[P"?<`K+S#ELG@W'B?RB&O*Q@D;82S";G5`(L"I,(]^
M;4QWEB-+,+UYI!P@;ZZW^!;P#B\4WY')H.K>4]KS6TE:D3-IX,F2':(4;>=L
MY"E>TM'5E9_V4(C57B\S7GA%L.N@_P#'`+28`P!@#`&`,`8`P!@#`&`,`8`P
M!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P"M9E#
M'+.2:^[G-8Q.3`JKU'#R8VM;!*EQ#BE6@5!=-'*`F(P@T$.PA\(=&:Z_XX!9
M/6M!UH(=:UK6M:UK6NFM:U^-:UK7XUK6L`_<`KOR.I5SN^/0MD;'AL9Q1BQ(
MW,U@G5*H6)UZ!EVJTI;0E$;UT-5@4>'6Q]0=.NMZWK>`?&CZ5?*5D-CMS9(&
M]95$H?C9/#HI^NK+<H8Y.`O,=V].<(0D9C,I,WXBP!\(@;`'_F+`+'8!B<]C
MI\OA$OBJ524C4R2-/3&G5G@&80F.=&Y0B+/.`7O1@RBAG:$+0?SO6OQ@$)<;
MJLM2G(NUP"6R6"O\/C;+M!']QYE>D#_M:8X#5F'NJQ>N.1J$WE'F!T$LD`O%
MTWO?36`69P#AN(%QK>N+;#R$KD8C5`;U*DG:A,G7#(&%(>H("(`CR"3]A$,&
MA:V(.MZZZZX!4>N>/5@D7?\`]=[=F<3?90WQ8R*,R""QQ5'VXU.?H0#W-Z&L
M4GJ5:W90Q!"'J((?%K7B\(`AP"XF`-_]G^/_``ZX!2]+QVLV5W;";9MV=0UT
M3UH:Z&Q-NA<75,K@X"6B.TD_N)>M5J-B+0E&Z_H*V((MAWT\/B%O8%T,`8`P
M!@&'V#&CYE!)E$4JDE$ID\7?6!.L4`&80E.=FU2A+4'%E]#!E$C/T(6@_G>M
M?C`*DU3Q0D]/R>II9%9<Q$+6&%:@MNMX4"\ENG[>F4&GMCJBT6/Q)GENT8'0
M##]"T+R@ZWOIL74"\V`,`INV43;D1OFQK8ADOK\#+9;C'MO+/(6)]6NB5G9P
M)RSR6]4B7I$Q3@>`)G@&/0R];V'>P_C>`7(P!@%27&C;+1<E'6](?*H6F:Y!
M'X]%7AB?VAY6N&F9M,1C<AMZE"M2IB7!1I+_`)(QZ&`'7^H.\`MM@#`*<KJ)
MMIFY"36ZX!+H`E2S=HC;`X,TJ8GQQ4IVQG_0VK$E.;EZ(H"U0-'ORQ;\00Z%
MKKK`+C8`P"G[SQ313VTK2L.R)`O7IY<TM,8B+9&'F01P;%&D"`TA6C>C&]<D
M+>?WUIGG")'H:?>^O4.][P"3>.E826FZL9ZYDLA028R.K'4EG<F].I2@`P*E
MQJQN0GE*MB'^PB_8&#>P[\'AT'ITZ8!.>`8!9+?8SE'-)ZN>XNPR72],8-3+
MVA6],REL"$X*Q":E0J$R@LU1L0/"9K8O#H.]=-]<`BSC30BBBH[*2'9_2R*3
MSF4K);(U36W::&),L4A\`$+(V^,>TZ(@.Q;UO?3>_%TT'00ZU@%DL`A/D15C
MA=-0RRMFMU1LJV1EMQ9+DX$GJ$J;])U1.`]FDIMZ.%XP)=AUT_PWO6`=A3L<
MLN)QLN/V*\PQZTT(VAJCAT0:79J\#8V-X$8_Y;3HM6?LK#1%`WH16BP].OX_
M.`2Y@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`,/F4^B5?H
MDCA+G;^(1KE6T24[]%R7^:IT4,[9?EMB-::#_*+WOQ"#H/XZ=>N`1Y]DZ4]Z
M:^/2OT+`'V3I3WIKX]*_0L`?9.E/>FOCTK]"P!]DZ4]Z:^/2OT+`'V3I3WIK
MX]*_0L`?9.E/>FOCTK]"P!]DZ4]Z:^/2OT+`'V3I3WIKX]*_0L`?9.E/>FOC
MTK]"P!]DZ4]Z:^/2OT+`'V3I3WIKX]*_0L`?9.E/>FOCTK]"P!]DZ4]Z:^/2
MOT+`'V3I3WIKX]*_0L`?9.E/>FOCTK]"P!]DZ4]Z:^/2OT+`'V3I3WIKX]*_
M0L`?9.E/>FOCTK]"P!]DZ4]Z:^/2OT+`'V3I3WIKX]*_0L`?9.E/>FOCTK]"
MP!]DZ4]Z:^/2OT+`'V3I3WIKX]*_0L`?9.E/>FOCTK]"P!]DZ4]Z:^/2OT+`
M'V3I3WIKX]*_0L`?9.E/>FOCTK]"P!]DZ4]Z:^/2OT+`'V3I3WIKX]*_0L`?
M9.E/>FOCTK]"P!]DZ4]Z:^/2OT+`'V3I3WIKX]*_0L`?9.E/>FOCTK]"P!]D
MZ4]Z:^/2OT+`'V3I3WIKX]*_0L`?9.E/>FOCTK]"P!]DZ4]Z:^/2OT+`'V3I
M3WIKX]*_0L`?9.E/>FOCTK]"P!]DZ4]Z:^/2OT+`'V3I3WIKX]*_0L`?9.E/
M>FOCTK]"P!]DZ4]Z:^/2OT+`'V3I3WIKX]*_0L`?9.E/>FOCTK]"P!]DZ4]Z
M:^/2OT+`'V3I3WIKX]*_0L`?9.E/>FOCTK]"P!]DZ4]Z:^/2OT+`'V3I3WIK
MX]*_0L`?9.E/>FOCTK]"P!]DZ4]Z:^/2OT+`'V3I3WIKX]*_0L`?9.E/>FOC
MTK]"P!]DZ4]Z:^/2OT+`'V3I3WIKX]*_0L`?9.E/>FOCTK]"P!]DZ4]Z:^/2
MOT+`'V3I3WIKX]*_0L`?9.E/>FOCTK]"P!]DZ4]Z:^/2OT+`'V3I3WIKX]*_
M0L`?9.E/>FOCTK]"P!]DZ4]Z:^/2OT+`'V3I3WIKX]*_0L`?9.E/>FOCTK]"
MP!]DZ4]Z:^/2OT+`'V3I3WIKX]*_0L`?9.E/>FOCTK]"P!]DZ4]Z:^/2OT+`
M'V3I3WIKX]*_0L`?9.E/>FOCTK]"P#\WR4I36M[W-==-:WO?_P`.RO\`PU^=
M_P#L+`)G;G!&[-Z%T;SOV$#BD3KD1_EFE><E5%!.(-\H\!9Q?F%#UOPC"$6N
+O3>M;P#FX`P#_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
